GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rated “Hold” by Sell-Side Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been assigned a consensus rating of “Hold” from the thirteen analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $4.23.

Several research analysts have issued reports on GDRX shares. Wells Fargo & Company increased their target price on shares of GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. TD Cowen upped their price target on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Barclays increased their price objective on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday, August 20th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $4.00 price objective on shares of GoodRx in a research note on Friday, August 7th.

GoodRx Stock Performance

GoodRx stock opened at $3.43 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The company has a market capitalization of $1.18 billion, a PE ratio of 85.77, a P/E/G ratio of 1.67 and a beta of 1.69. The company has a 50 day moving average price of $3.46 and a 200-day moving average price of $2.91. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $4.72.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%. The company had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. During the same period last year, the business posted $0.09 EPS. GoodRx’s quarterly revenue was down 1.3% on a year-over-year basis. As a group, equities analysts forecast that GoodRx will post 0.16 earnings per share for the current year.

Insider Transactions at GoodRx

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total value of $4,536,619.50. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders sold 2,760,995 shares of company stock worth $9,673,207. 5.87% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GoodRx

A number of hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LP bought a new position in GoodRx in the second quarter worth about $86,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of GoodRx during the 2nd quarter worth approximately $500,000. Headlands Technologies LLC bought a new position in shares of GoodRx during the 2nd quarter worth approximately $30,000. Technology Crossover Management X Ltd. purchased a new stake in GoodRx during the second quarter valued at approximately $4,762,000. Finally, Bank of New York Mellon Corp purchased a new stake in GoodRx during the second quarter valued at approximately $540,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc operates a healthcare technology platform that helps consumers find prescription medications at lower prices. Through its website and mobile applications, GoodRx allows users to compare prescription prices at participating pharmacies, access discount coupons and identify potential savings on commonly prescribed medications. The company’s services are primarily focused on the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as telehealth services that connect consumers with healthcare providers for certain medical consultations and prescriptions.